Abstract
Background Investigating the role of late presenters (LP) on HIV-1 transmission is important, as they can contribute to the onward spread of HIV-1 virus in the long period before diagnosis, when they are not aware of their HIV status
Objective To describe the clinical and socio-demographic characteristics of HIV-1 infected individuals followed in Europe, to characterize patients in clusters and to compare transmission clusters (TC) in LP vs non-late presenters (NLP) populations.
Methods Clinical, socio-demographic and genotypic information from 38531 HIV-1 infected patients was collected from the EuResist Integrated Database (EIDB) between 1981 and 2019. Sequences were aligned using VIRULIGN. Maximum likelihood (ML) phylogenies were constructed using FastTree. Putative transmission clusters were identified using ClusterPicker v1.332. Statistical analyses were performed using R.
Results 32652 (84·7%) sequences were from subtype B, 3603 (9·4%) were from subtype G, and 2276 (5·9%) were from subtype A. The median age was 33 (IQR: 26·0-41·0) years old and 75·5% of patients were males. The main transmission route was through homosexual (MSM) contact (36·9%) and 86·4% were originated from Western Europe. Most patients were native (84·2%), 59·6% had a chronic infection, and 73·4% had acquired drug resistance (ADR). CD4 count and viral load at diagnosis (log10) presented a median of 341 cells/mm3, and of log10 4·3 copies/mL, respectively. 51·4% of patients were classified as LP and 21·6% patients were inside TCs. Most patients from subtype B (85·6%) were in clusters, compared to subtypes A (5·2%) and G (9·2%). Phylogenetic analyses showed consistent clustering of MSM individuals. In subtype A, patients in TCs were more frequently MSM patients and with a recent infection. For subtype B, patients in TCs were more frequently those with older age (≥ 56), MSM transmission route, originating from Western Europe, migrants, and with a recent infection. For subtype G, patients in TC were more frequently patients with recent infection and migrants. When analysing cluster size, we found that NLP more frequently belonged to large clusters (>8 patients) when compared to LP.
Conclusion While late presentation is still a threat to HIV-1 transmission, LP individuals are more present either outside or in small clusters, indicating a limited role of late presentation to HIV-1 transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financed by FCT through the following projects: GHTM- UID/04413/2020, INTEGRIV (PTDC/SAU-INF/31990/2017) and the scholarship PD/BD/135714/2018 and COVID/BD/152613/2022 and Gilead Genese HIVLatePresenters.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed in this study were in accordance with the ethical standards of the ethical committee of the Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa and with the 1964 Helsinki declaration. The database enrolled anonymized patients information, including demographic, clinical and genomic data from patients from the EuResist Integrated Database (Date of approval: 15 January 2021)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
martapingarilho{at}ihmt.unl.pt (M.P.); victor.pimentel{at}ihmt.unl.pt (V.P.); mrfom{at}ihmt.unl.pt (M.d.R.O.M.); sgseabra{at}ihmt.unl.pt (S.G.S); ana.abecasis{at}ihmt.unl.pt (A.A.); pcrsilva{at}chlo.min-saude.pt (P.G); rolf.Kaiser{at}uk-koeln.de (R.K.); michael.boehm{at}uk-koeln.de (M.B.); carole.devaux{at}lih.lu (C.S.-D.); rparedes{at}irsicaixa.es (R.P.); mrbobkova{at}mail.ru (M.B.); maurizio.zazzi{at}unisi.it (M.Z.); f.incardona{at}informa.pro (F.I.)
Data Availability
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s. The use of the EuResist database is available upon request through a study proposal submission.
